Suven Pharmaceuticals

Suven Pharma shares surge 3% as Goldman Sachs initiates ‘Buy’ rating with Rs 1,350 target

Suven Pharma shares jump 7% as Q3 net profit rises 77% YoY

Suven Pharmaceuticals acquires 56% stake in NJ Bio for Rs 533 crore

This development aligns with Suven’s vision to broaden its footprint in high-growth areas of the healthcare industry while delivering enhanced value to its shareholders.

Suven Pharmaceuticals acquires 56% stake in NJ Bio for Rs 545.32 crore

Suven Pharmaceuticals shares jump over 5% after acquiring Sapala Organics